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Chronic  constipation  is  a  very  common  symptom  that  is  rarely  associated  with  life-threatening  diseases,
but  has  a  substantial  impact  on  patient  quality  of  life and  consumption  of  healthcare  resources.  Despite
the  large  number  of  affected  patients  and  the  social  relevance  of  the condition,  no  cost-effectiveness
analysis  has  been  made  of  any  diagnostic  or  therapeutic  algorithm,  and  there  are  few  data  comparing
different  diagnostic  and  therapeutic  approaches  in the  long  term.  In this  scenario,  increasing  emphasis
has been  placed  on  demonstrating  that  a  number  of  older  and  new  therapeutic  options  are  effective  inonstipation
vidence-based medicine
treating chronic  constipation  in well-performed  randomised  controlled  trials,  but  there  is still  debate
as to  when  these  therapeutic  options  should  be included  in diagnostic  and therapeutic  algorithms.  The
aim of  this  review  is to  perform  a critical  evaluation  of  the  current  diagnostic  and  therapeutic  options
available  for  adult  patients  with  chronic  constipation  in  order  to identify  a rational  patient  approach;
furthermore  we attempt  to clarify  some  of  the  more  controversial  points  to  aid  clinicians  in managing
this  symptom  in a more  efﬁcacious  and  cost-effective  manner.
 Gast© 2013 Editrice
. Introduction
Chronic constipation is a very common and heterogeneous con-
ition characterised by unsatisfying defecation associated with
nfrequent stools, difﬁcult stool passage, or both [1]. It has a
revalence of 14% in the general population [2], and a signiﬁcant
mpact on patient quality of life [3,4], working productivity [5],
nd consumption of healthcare resources [6]. Over the last ten
ears, both old and new treatments with different mechanisms
f action have proved to be effective [7], but their role in the
herapeutic approach still needs to be optimised. The aim of this
eview is to perform a critical evaluation of the diagnosis and treat-
ent of chronic constipation in adults, concentrating on the most
ontroversial issues raised by the current availability of effective
reatments. Take-home messages are included at the end of each
ection.
.1. DeﬁnitionsThere are various deﬁnitions of chronic constipation, and the
pparently small differences between them need to be acknowl-
dged as they create groups of patients with potentially distinct
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responses to treatments. One of the most widely used is based on
the Rome III criteria (Table 1) [8]. Whether the combination of two
or more different symptoms identiﬁes different subsets of patients
remains unclear [9,10], as whether a bowel diary is needed to over-
come the discrepancy between recalled and recorded bowel habits
[11,12].
An alternative approach is to deﬁne constipation on the basis
of a patient’s dissatisfaction with the frequency of defecation and
stool passage [1]. This approach is underpinned by the concept that
it is the patients’ perceived degree of dissatisfaction that makes a
symptom more or less relevant. There are no details as to how this
should be measured, but the symptoms should be considered clini-
cally important and treated when they are severe enough to impair
the patient’s quality of life [1], a variable that is also inﬂuenced
by psychological factors [13]. Moreover, the challenge of a deﬁni-
tion based on dissatisfaction is that many people have their own,
possibly erroneous conception of what constitutes a normal bowel
habit: for example, elderly patients with normal bowel frequency
(>3 times/week) often regard themselves as being constipated and
take laxatives [14].
A third deﬁnition used in clinical trials is a modiﬁed version of
the Rome criteria in which abnormal bowel frequency (<3 bowel
movements/week) is the necessary condition for inclusion [15–19].
This restriction makes the patients more uniform and provides an
objective parameter for assessing treatment efﬁcacy, but excludes
the important subgroup of patients who  feel constipated despite
normal bowel frequency [11,14]. It might also limit the possibility
of extrapolating clinical trial results to the general population and
 Ltd. All rights reserved.
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Table 1
Rome III functional constipation criteria.a
1. Must include at least 2 of the following:
a.  Straining during at least 25% of defecations
b.  Lumpy or hard stools in at least 25% of defecations
c. Sensation of incomplete evacuation for at lest 25% of defecations
d.  Sensation of anorectal obstruction/blockage for at least 25% of
defecations
e.  Manual manoeuvres to facilitate at least 25% of defecations (e.g. digital
evacuation, support of the pelvic ﬂoor)
f.  Fewer than three defecations per week
2. Loose stools are rarely present without the use of laxatives
3.  Insufﬁcient criteria for diagnosis of irritable bowel syndrome
a Criteria fulﬁlled for the previous three months with symptom onset at least six
months prior to diagnosis.
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Table 2
Classes of medications (examples) and diseases associated with secondary consti-
pation [24,25].
Medications: Opiates (morphine), anticholinergic agents,
tricyclic antidepressants (amitriptyline),
antispasmodics (dicyclomine, mebeverine,
peppermint oil), calcium channel blockers
(verapamil, nifedipine), antiparkinsonian drugs,
anticonvulsants (carbamazepine),
sympathomimetics (ephedrine), antipsychotics
(chloropromazine, clozapine, haloperidol,
risperidone), diuretics (furosemide),
antihypertensives (clonidine), antiarrhythmics
(amiodarone), beta-adrenoceptor antagonists
(atenolol), antihistamines, calcium or aluminium
containing antacids, calcium supplements, iron
supplements, antidiarrheal (loperamide),
5-HT3-receptor antagonists (ondansetron), bile
acid sequestrants (cholestyramine), non-steroidal
anti-inﬂammatory drugs (ibuprofen)
Organic stenosis: Colorectal cancer; other intra- or extra-intestinal
masses; inﬂammatory, ischemic or surgical
stenosis
Endocrine or metabolic
disorders:
Hypothyroidism, hypercalcemia,
hyperparathyroidism, diabetes, porphyria, chronic
renal insufﬁciency, pan-hypopituitarism,
pregnancy
Neurological disorders: Spinal cord injury, Parkinson’s disease,
cerebrovascular disease, paraplegia, multiple
sclerosis, autonomic neuropathy, spina biﬁda
Enteric neuropathies: Hirschsprung’s disease, chronic intestinal
pseudo-obstruction
Myogenic disorders: Myotonic dystrophy, dermatomyositis,
scleroderma, amyloidosis, chronic intestinal
pseudo-obstructionhe elderly, in whom the major complaints deﬁning constipation
re straining and hard stools rather than reduced bowel frequency
14,20].
Another debated point is whether irritable bowel syn-
rome with constipation (IBS-C) is a different entity from
hronic/functional constipation. Some researchers consider the
wo conditions indistinguishable [1] because the abdominal pain
nd discomfort characterising IBS can also be associated with
onstipation [21,22]. Furthermore, although the Rome III criteria
xclude IBS-C from the deﬁnition of functional constipation [8], if
his requirement is not enforced, there is a large overlap between
he two [23]. These observations suggest a continuum based on the
everity of pain or discomfort [23], but do not exclude the possi-
ility that the patients at the two extremes of the spectrum may
eneﬁt more from treatment aimed speciﬁcally at relieving abdom-
nal pain or correcting the defecation disorder/colonic transit. In
articular, the presence of abdominal pain in patients with chronic
onstipation is associated with a poorer quality of life and more
requent extra-intestinal somatic symptoms than in constipated
atients with no abdominal pain [21].
Take-home messages (1)
The different deﬁnitions of chronic constipation create groups
f patients with potentially distinct treatment responses.
Physicians prefer using objective and physical factors when
eﬁning constipation, whereas patient dissatisfaction may  be unre-
ated to these factors.
Chronic constipation and irritable bowel syndrome with consti-
ation often overlap.
. Causes and pathophysiology
Most cases of chronic constipation are primary or idiopathic,
ut it is also necessary to acknowledge that a few cases may  be
econdary to a number of medications or diseases (Table 2) [24,25],
ecause reducing or stopping the medications or treating the pri-
ary diseases may  help to relieve the symptom. The long and
eterogeneous list of conditions that induce constipation indicates
hat many pathophysiological mechanisms ﬁnally cause the same
ymptoms, which are often indistinguishable from those of the
rimary form.
The pathophysiology of primary chronic constipation is mul-
ifactorial and includes diet, colonic motility and absorption,
norectal motor and sensory function, and behavioural and psy-
hological factors. Most studies have investigated the impact of
nly one factor at a time, whereas their multiplicity, overlapping
ature, and bidirectional interplay should be taken into account in
rder to avoid oversimpliﬁcation. Although it is conceivable that
 better understanding of the pathophysiology of the condition
ight help in the planning of more rational therapy, the complexAnorectal disorders: Anal ﬁssures, anal strictures
interactions of various pathophysiological factors suggest that ther-
apeutic strategies based on only one of them should be considered
with caution.
2.1. Diet
A ﬁbre-rich diet accelerates transit time, softens stool and
increases stool weight, but a diet that is poor in ﬁbre can induce
constipation [26]. However, the consumption of dietary ﬁbre is no
different between constipated and non-constipated subjects [27].
Increasing dietary ﬁbre improves symptoms in patients with nor-
mal  colonic transit and anorectal function, but not in constipated
patients with delayed colonic transit and defecation disorders
[28,29]. The latter are characterised by low stool weight and pro-
longed transit times regardless of the amount of ﬁbre in their diet
[26], which suggests that increasing their ﬁbre intake does not nor-
malise colonic transit and can even worsen their symptoms as a
result of the gas produced by ﬁbre metabolism.
2.2. Colonic motility and absorption
Delayed colonic transit is associated with small and hard stools
[30] that are difﬁcult to evacuate [31,32]. It has been found that
faecal consistency and water content signiﬁcantly correlate with
colonic transit time [33], which suggests that prolonged colonic
transit favours the time-dependent process of water absorption.
Moreover, changes in colonic transit affect bacterial mass [34], and
this may  also inﬂuence colonic absorption and secretion.
Delayed colonic transit may  be due to impaired colonic motor
activity [35], but may  also be secondary to voluntary stool reten-
tion [36], defecation disorders [37,38], or an inadequate caloric
intake [39–41]. Studies of colectomy samples taken from patients
with delayed colonic transit suggest that impaired motility might
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e caused by abnormalities in interstitial cells of Cajal [42] or
he overexpression of progesterone receptors in colonic circular
uscle cells [43,44]. However, the normalisation of delayed tran-
it after behavioural treatment in such patients [45], and changes
n the male/female incidence ratio of constipation in patients
ged > 60 years [46], suggest that structural abnormalities should
ot be considered an irreversible cause of impaired colonic motil-
ty.
.3. Anorectal motor and sensory functions
Constipated patients frequently complain of difﬁculties in satis-
actorily evacuating rectal contents, and the absence of a normal
all for evacuation. Normal defecation requires a very complex
nteraction between colorectal motor and sensory functions that
eeds to be coupled with appropriate behaviour: the rectosigmoid
as to be loaded with normal stools, rectal distension has to be
ormally perceived, and the voluntary act of defecation (abdom-
nal contraction, and puborectalis and anal relaxation) has to be
erformed at the right time. A number of alterations in these
unctions have been observed in patients with defecation disor-
ers, including: (1) a failure of external anal sphincter-puborectalis
elaxation when attempting defecation (anismus) [47,48]; (2) a
ypertonic internal anal sphincter [38,49]; (3) inadequate rectal
ropulsion during defecation [48]; (4) rectal hyposensitivity and
ypotonicity [50]; (5) anatomical anorectal alterations such as
arge rectoceles or rectal prolapse [51,52]; (6) excessive perineal
escent [49]; and (7) the uncoupling of the sensory component
urge to defecate) and the normal pre-defecatory motor activity of
he colon [53]. These dysfunctions may  co-exist and, when they
o, it is unclear whether they are primary or secondary to con-
tipation. It is also necessary to remember that the alterations
re often unspeciﬁc (i.e. they can be found in normally defecat-
ng healthy subjects), and their assessment is greatly inﬂuenced
y the way in which the voluntary act of defecation is performed,
hich may  vary depending on the subject’s degree of participa-
ion.
.4. Behavioural factors
Withholding behaviour after experiencing a difﬁcult and painful
owel movement is known to induce functional constipation in
hildren [54], and leads to stool retention, rectal distension, and
verﬂow faecal incontinence. The problem may  persist into young
dulthood [55], and returns to being a major cause of constipation
n elderly hospitalised patients whose persistent disregard of the
all to stool may  lead to faecal impaction [56].
.5. Psychological factors
Patients with constipation frequently have psychological mor-
idities in various domains (including somatisation, anxiety, and
epression) [57], but it is difﬁcult to establish how these alterations
ffect the pathophysiological factors underlying constipation in
ndividual cases. Adverse life events, such as the loss of a par-
nt, sexual or physical abuse [58], discrepancies between reported
owel symptoms and objective alterations [11,59], a concomitant
ating disorder [39,40], dissatisfaction with standard treatments,
nd demanding or angry behaviour [60] all suggest an underlying
sychological alteration or psychiatric diagnosis.
Take-home messages (2)
The multiplicity of conditions associated with chronic con-
tipation suggests that the pathophysiology of the condition is
ulti-factorial and involves alterations in behavioural, colorectal
nd psychological factors.iver Disease 45 (2013) 886– 893
3. Diagnosis
3.1. Clinical evaluation
A detailed clinical evaluation and rectal examination are the two
most important steps when diagnosing chronic constipation [24].
The features that each patient rates as the most distressing should
be deﬁned and represent the ﬁrst target of treatment: is the patient
unsatisﬁed with the frequency or consistency of defecation, or is
it the act of defecation that is difﬁcult? It has been found that a
feeling of incomplete evacuation, a sense of obstruction, and digi-
tal evacuation are all associated with defecation disorders [61]. An
overlap with IBS is suggested by complaints of bloating and abdom-
inal pain between defecations. A dietary review should not only
consider the reduced ﬁbre intake that may  cause constipation, but
also the possibility that a normal or excessive ﬁbre intake can cause
bloating and abdominal pain, particularly in patients with delayed
transit. The different treatments that have been tried should be
recorded in order to verify and optimise the doses and schedules
of treatments. Bowel habits should be monitored, preferably with
the aid of diary cards and a Bristol stool form because patient
recall may  be misleading [11,12]. Furthermore, any adverse life
events, psychological disturbances, eating disorders, or behavioural
modiﬁcations that may  inﬂuence the act of defecation should be
investigated [24].
Clinical evaluation should also consider the possibility of a sec-
ondary cause of constipation (Table 2) which although rare in
the case of chronic symptoms, is often treatable. In most cases,
a detailed clinical history is sufﬁcient to identify the diseases or
medications that may  cause constipation. It is debated whether
laboratory tests (complete blood counts, calcium levels, thyroid
stimulating hormone) and colonoscopy should be routinely used to
exclude organic disorders in patients with chronic constipation. The
ACG recommends diagnostic studies for patients with alarm symp-
toms (hematochezia, weight loss, a family history of colon cancer or
inﬂammatory bowel disease, anemia, positive faecal occult blood
tests, and the acute onset of constipation in elderly subjects), or
symptoms suggesting an organic disorder. The routine use of colon
cancer screening is also indicated in all patients aged > 50 years [1].
All patients with chronic constipation should undergo a rectal
examination [62] in order to look for causes of anal pain (such as
ﬁssures or thrombosed haemorrhoids) that may  precipitate or be
secondary to constipation. An anal contraction in response to a
gentle stroke on the perianal skin excludes damage to the sacral
nerve pathways. Palpation with the index ﬁnger should include a
search for faecal impaction, which is often associated with a his-
tory of soiling and needs speciﬁc treatment. Resting sphincter tone
should be assessed because, if it is increased, it may contribute to
evacuation difﬁculties; digital assessments of anal tone at rest and
during squeezing correlate with the pressures measured by means
of manometry [63,64]. The anterior wall should be checked for the
presence of a rectocele. The patient should then be asked to strain
and try to push out the ﬁnger: the anal sphincter and pubo-rectalis
should relax, and the perineum should descend less than 3.5 cm
[62].
At this stage, as the nature of the symptoms disturbing the
patient will have been clariﬁed, secondary causes will have been
reasonably excluded, and any dietary or behavioural abnormali-
ties will have been corrected, an interpretative framework of the
mechanisms underlying the symptoms can be offered to the patient
and followed by treatment [1] with laxatives such as polyethylene
glycol, sodium picosulfate or bisacodyl.Take-home messages (3)
Patients with chronic constipation should undergo careful clini-
cal evaluation including a rectal examination to identify those who
require additional tests to seek secondary causes. However, in the
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bsence of alarm symptoms, empiric treatment can be started with-
ut any previous diagnostic testing.
.2. Physiological studies of refractory constipation
If constipation fails to improve (refractory constipation), most
xperts suggest referring the patient for physiological studies of
norectal function (balloon expulsion tests, anorectal manometry,
efecography) and colonic transit in order to establish whether he
r she has a functional defecation disorder or slow transit consti-
ation.
.2.1. Rectal balloon expulsion test
This test is carried out by measuring the time required to expel a
ectal balloon ﬁlled with 50 mL  of water [65] or the volume induc-
ng a sustained desire to defecate [66]. Most centres consider > 60 s
bnormal [66], but up to 5 min  has been used [65]. The test is inﬂu-
nced by body position and (like all tests measuring defecatory
unction) the patient’s understanding and willingness to perform
he voluntary act of defecation. Up to 16% of healthy subjects have
ifﬁculties in expelling the balloon [48].
.2.2. Anorectal manometry
Anorectal manometry is performed by inserting a pressure-
ensitive catheter with a balloon at its tip in the anal canal.
ethods vary widely between different centres, and high-
esolution manometry has recently been introduced [67]. Anorectal
anometry provides information concerning the neuromuscular
nd sensory function of the anorectum and, in the rare patients
ith megarectum/megacolon, is useful for assessing the presence
f the recto-anal inhibitory reﬂex which, when absent, may  indi-
ate Hirschsprung’s disease or visceral neuropathy [68,69]. In most
hronically constipated patients without bowel dilatation, the test
as been used to assess the patterns of rectal and anal pressure
uring attempted defecation: a normal pattern is characterised
y a >45 mmHg  increase in intrarectal pressure associated with a
20% reduction in anal pressure. Traditional manometry reveals a
on-synergistic pattern in 20% of normal subjects [48,70], and the
ame is found upon high-resolution manometry in all women  aged
50 years [67]. These ﬁndings limit the usefulness of the rectoanal
radient during simulated evacuation as a means of diagnosing
efecatory disorders.
.2.3. Defecography
Defecography is performed by placing barium paste in the rec-
um, and studying the function of the anorectal region at rest and
uring attempted defecation by means of ﬂuoroscopy [71]. A mag-
etic resonance imaging-based variant of defecograpy can also be
sed in order to avoid radiation exposure and allow visualisa-
ion of the perirectal structures [49]. The defecographic features of
isordered defecation include incomplete anal opening, impaired
ubo-rectalis relaxation or paradoxical pubo-rectalis contraction,
educed or increased perineal descent, and an inability to expel or
etain rectal contents. In addition, defecography may  reveal struc-
ural abnormalities such as rectoceles, enteroceles, rectal prolapse
nd intussusception. However, there are few data concerning nor-
al  values in healthy subjects, a substantial proportion of whom
ave both functional and structural alterations [49,71,72].
.2.4. Colonic transit
Colonic transit can be assessed using radio-opaque markers [73],
adioscintigraphy [38], or a wireless motility capsule [31,74]. The
echnique of Metcalf et al. is one of the most standardised in healthy
ubjects and minimises radiation exposure [73]. It involves the
dministration of 20 radio-opaque markers on days 1, 2 and 3, and
he remaining markers are counted by means of a high-kilovoltage,iver Disease 45 (2013) 886– 893 889
fast-ﬁlm, plain abdominal X-ray on day 4. Colonic transit is cal-
culated in hours: 1.2× the number of markers. The upper 95th
percentile in healthy subjects is 68 h [73].
3.2.5. Constipation sub-types
Depending on the results of these tests, chronic constipation
can be categorised into three main sub-types: slow transit consti-
pation, defecation disorder (with normal or delayed transit), and
constipation with normal test results. Anorectal tests are useful
when diagnosing defecatory disorders for which biofeedback is
superior to laxatives in managing constipation [75]. Diagnosing
slow transit constipation requires an assessment of colonic transit,
which may  warrant colectomy in patients with medically refrac-
tory symptoms [76]. However, the usefulness of assessing colonic
transit and anorectal function is limited by a number of factors, and
is still a subject of debate [77]. First of all, the association between
symptoms and the sub-types deﬁned on the basis of physiological
tests is limited [9,10]. Secondly there is no gold standard anorec-
tal test for diagnosing defecatory disorders, and there is limited
concordance between the physiological tests [78]. Lastly, there is
limited evidence that the test results have an impact on therapy.
Two  studies have shown that impaired rectal balloon expulsion
is associated with a more favourable biofeedback outcome [65,79],
which suggests that an abnormal result might be used to select can-
didates for this treatment, and explains why  some experts indicate
that anorectal function tests should be performed early [24,80,81].
However, others say that they may  be delayed until all of the avail-
able treatments have been tried [25], or that they may not be
needed at all [82]. In relation to colonic transit, three uncontrolled
studies have found that patients with delayed transit show a poor
response to ﬁbre intake [27–29], which suggests that other ther-
apeutic approaches may  be preferable. A further two studies have
found more psychosocial disturbances in constipated patients with
normal colonic transit [11,59], which is in line with the suggestion
that colonic transit is an excellent point of communication with
patients that helps to clarify the meaning of symptoms and provides
a framework in which to explain them [82]. However, whether
these ﬁndings justify the extensive use of physiological diagnos-
tic testing in the large population of constipated patients who fail
to respond to the ﬁrst laxative treatment remains an open ques-
tion [1,24,25,77,82]. In an ethic of avoiding waste [83], their more
restricted use may  be recommended and formal cost-effectiveness
analyses should be made in order to validate the proposed diag-
nostic algorithms.
Take-home messages (4)
Physiological tests (balloon expulsion test, anorectal manome-
try, defecography and colonic transit) for chronic constipation are
not standardised and are non-speciﬁc.
The classiﬁcation of patients with refractory constipation into
patho-physiological subtypes lacks cost-effectiveness validation.
4. Management
There are many evidence-based therapeutic approaches to the
treatment of chronic constipation, including biofeedback, osmotic
and stimulant laxatives, and new pharmacological therapies that
have different mechanisms of action and side effects.
4.1. Fibre supplements
Fibre supplements are traditionally considered the ﬁrst-line
treatment, although deﬁcient ﬁbre intake in patients with chronic
constipation has not been demonstrated at referral centres [27],
and there is little evidence that insoluble ﬁbres are beneﬁcial [84].
Fibre supplements are less effective in patients with slow tran-
sit constipation or defecatory disorders than in those with normal
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Table  3
Mechanisms of action and side effects of evidence-based pharmacological approaches for chronic constipation [7].
Treatments and doses Mechanisms of action and main advantages % Response vs placebo.
Number needed to
treat (95% CI)
Duration of
controlled trials
Disadvantages
Osmotic laxatives:
polyethylene glycol 17 g
daily
More water is drawn into the colon. Not absorbed
systemically
61% vs 31% NNT = 3
(2–4)
6 months Abdominal distension,
ﬂatulence, nausea,
diarrhoea
Stimulant laxatives: bisacodyl
and sodium picosulfate
5–10 mg  daily
Increased colonic contractions; anti-absorptive
secretory effects. Not absorbed and activated in the
colon
58% vs 22% NNT = 3
(2–4)
4 weeks Abdominal pain,
diarrhoea
Prokinetic: prucalopride
1–2 mg  daily
Serotonin 5-HT4 receptor agonist; accelerates
gastrointestinal and colonic transit
28% vs 13% NNT = 6
(5–9)
12 weeks Headache, nausea,
diarrhoea
Secretagogue: lubiprostone
24 g twice daily
Chloride channel activator; increased intestinal ﬂuid
secretion
55% vs 33% NNT = 4
(3–7)
4 weeks Nausea, diarrhoea.
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pSecretagogue: linaclotide
145–290 g daily
Guanylate cyclase C receptor agonist; increase
intestinal ﬂuid secretion. Analgesic effect [89]
ransit constipation [29]; they are generally safe, but may  increase
loating, ﬂatulence and abdominal pain, and may  interfere with the
bsorption of some drugs [84]. A soluble ﬁbre (psyllium) may  ben-
ﬁt some patients with chronic constipation but, unlike osmotic
nd stimulant laxatives and the newer pharmacological agents,
his treatment is supported by poor quality data [84], and one
tudy has found that treatment with polyethylene glycol (PEG)
as faster and more effective [85]. Taken together, these obser-
ations suggest that, rather than ﬁbre supplementation, osmotic
nd stimulant laxatives should be considered for the ﬁrst-line
reatment of patients with chronic constipation seen at referral
entres.
.2. Biofeedback
This represents a behavioural treatment in which patients
earn the physiological mechanisms of defecation, and how to
se their diaphragms and abdominal and pelvic ﬂoor muscles in
rder to evacuate. Sensory retraining may  also be provided [86].
atient motivation and the expertise of the therapist are criti-
al but not standardised factors that affect therapeutic responses.
andomised clinical trials have shown that biofeedback is more
ffective than both sham feedback and laxatives [86,87,75], par-
icularly in the sub-group of patients with defecation disorders
s 76% responded to bio-feedback and only 46% to standard lax-
tive therapy [75,86]. However, experienced therapists are not
idely available, and some experts have suggested that biofeed-
ack should only be proposed after all of the other available
reatments have been tried [25], although others indicate it as the
rst-line treatment for patients with defecation disorders [80,81].
nterestingly, the instrumental feedback might be less impor-
ant than the interaction with the therapist [87], which suggests
hat verbal instructions from dedicated physicians or other tech-
iques of home training may  prove to be effective in the future
88].
.3. Evidence-based pharmacological approaches
A recent systematic review and meta-analysis [7] has found that
olyethylene glycol (PEG), sodium picosulfate, bisacodyl, prucalo-
ride, lubiprostone and linaclotite are more effective than placebo
n treating chronic constipation. Table 3 summarises the main
dvantages and disadvantages of these treatments emerging from
andomised controlled trials, together with their efﬁcacy. These
esults do not allow any head-to head comparison between the dif-
erent treatments: the striking differences in the placebo responses
5–33%) in the different studies suggest more differences between
atient populations or efﬁcacy endpoints than true differencespregnancy
21% vs 5% NNT = 6 (5–8) 12 weeks Diarrhoea
between treatments. Whatever the efﬁcacy endpoint, a substantial
proportion of patients remained unsatisﬁed with the treatments
[90]. The deﬁnition of, and clinical approach to patients with “difﬁ-
cult”, “refractory” or “intractable” constipation is still unclear [91].
The degree of patient dissatisfaction may  be due to inefﬁcacy and/or
the side effects of treatments [90], or psychological alterations
[60,92], but it is not known what the relative role of these factors
is.
Most studies have not deﬁned patient sub-types, and so it is
unknown whether a better response can be obtained in certain sub-
groups. Suppositories, enemas and other concomitant laxatives
have been allowed as “rescue” therapies during pharmacologi-
cal trials, but how to optimise combined therapies with different
mechanisms of action, or how and when to use rectal therapies,
has been poorly investigated [91]. How long the patients should be
treated and the long-term safety proﬁle of treatments remain rel-
atively unknown, although PEG and prucalopride have been safely
used for more than two years [93,94].
4.4. Other approaches
In highly selected patients treatment strategies may  include
sacral nerve stimulation or surgery. However, the substantial mor-
bidity and variable outcomes associated with these treatments
should limit their use, with special arrangements being made for
consent, audits or research [95].
Sacral nerve stimulation is based on the continuous low-
amplitude electrical stimulation of sacral nerve roots, and has been
claimed to be effective in patients with intractable constipation
[96]. However, other studies with a median follow-up of more
than two  years have reported successful outcomes in only 29%
of patients [97], and at least one event leading to failure in 58%
(surgery in 33%) [98].
Of the surgical procedures, colectomy with ileorectal anas-
tomosis is performed in patients with refractory slow transit
constipation in whom a concomitant defecation disorder has been
excluded or treated [76]. Between 39% and 100% of patients have
said they were satisﬁed with the procedure [99]. A number of side
effects have been reported, including abdominal pain, small bowel
obstruction and re-operation, with prevalence rates varying from
0% to 90% [99]. The outcome may  be worse in patients with co-
existing psychiatric disturbances [100] and disordered motility in
the higher segments of the gastrointestinal tract [101].
Stapled transanal rectal resection (STARR) of the redundant
rectal mucosa has been proposed for patients with defecation dis-
orders associated with the presence of rectoceles or internal rectal
prolapse at defecography [102]. However the causal relationship
between these conditions and symptoms remains uncertain as
 and Liver Disease 45 (2013) 886– 893 891
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Table 4
Emerging drugs for chronic constipation and irritable bowel syndrome-C.
Name Class and mechanism of action Status of clinical
studies
Naronapride 5-HT4 receptor agonist: prokinetic Phase III
Velusetrag 5-HT4 receptor agonist: prokinetic Phase III
Pumosetrag 5-HT3 receptor agonist: prokinetic Phase II
Alvimopan Opioid receptor antagonist Phase III
Methylnaltrexone Opioid receptor antagonist Phase III
Plecanatide Colonic secretagogue: activation of
guanylate cyclase C receptor
Phase IIaG. Basilisco, M. Coletta / Digestive
ectoceles and internal rectal prolapse can also be encountered in
ormally defecating subjects [71]. One randomised trial found that
TARR was superior to bio-feedback, with success rates of respec-
ively 81% and 33%; however, there was an unusual drop-out rate
f 50% in the bio-feedback arm [103]. The results seem to be less
ncouraging after a longer follow-up [104,105]. An overall post-
rocedural morbidity rate of 36% has also been reported, including
aecal urge incontinence, severe anorectal pain and anorectal
epsis [106]. Laparoscopic ventral rectopexy has been used as an
lternative with promising short-term results in patients with a
efecation disorder and internal rectal prolapse [52].
Take-home messages (5)
Evidence-based therapeutic approaches are available for the
reatment of chronic constipation, and should be preferred over
reatments that continue to be recommended despite the lack of
onvincing evidence of efﬁcacy.
The efﬁcacy and side effects of surgical procedures for chronic
onstipation vary widely among centres. The morbidity reported
fter surgery discourages the unrestricted use of these therapeutic
pproaches.
.5. Secondary constipation
In most cases, the therapeutic approach is similar to that used
or the primary form but, in some cases, the causes are so speciﬁc
hat they allow targeted treatment. Some examples are methylnal-
rexone or alvimopan for opioid-induced constipation [107], and
peciﬁc behavioural training and retrograde cleansing programmes
or patients with spinal cord injuries, multiple sclerosis or spina
iﬁda [108].
.5.1. Pregnancy
Constipation is frequent during pregnancy: osmotic and stimu-
ant laxatives are not absorbed systemically, and their use has not
een (and is not expected to be) associated with an increased risk
f malformations [109]; stimulant laxatives are more effective than
ulk-forming agents but may  cause more side effects [110].
.5.2. Intestinal pseudo-obstruction
It has been shown that prucalopride improves bloating and
bdominal pain in the few constipated patients in whom gut
ilatation is the manifestation of severe and widespread enteric
europathy or myopathy (intestinal pseudo-obstruction) [111].
.5.3. Faecal impaction
Impacted stools in the rectum should be fragmented and
emoved with enemas before titrating an osmotic laxative [112].
reliminary data suggest that a combination of high-dose osmotic
nd stimulant laxatives can be safely and efﬁciently given to elderly
atients with faecal impaction [113].
.6. Emerging pharmacological therapies
Table 4 summarises the new pharmacological therapies for
hronic constipation and IBS-C that are still under evaluation.
aronapride (ATI-7505) and Velusetrag (TD-5108) are two sero-
onin 5-HT4 receptor agonists similar to prucalopride that increase
olonic motility and are less likely to have cardiovascular side
ffects because of their receptorial selectivity [114–116]. Pumose-
rag (MKC-733, DDP-733) is a partial 5-HT3 receptor agonist that
ccelerates gastrointestinal transit, increases stool frequency, and
mproves straining and the sensation of incomplete evacuation; it
as been proposed for patients with IBS-C [117]. Alvimopam and
ethynaltrexone are peripherally acting mu-opioid antagonists
hat have been developed to restore the constipation induced byElobixibat Inhibition of bile acid reabsorption:
prokinetic and secretagogue
Phase IIb
5-HT: serotonin.
opioids [107]. Plecanatide (SP-304) is a guanylate-cyclase C recep-
tor agonist that stimulates luminal chloride secretion and has an
effect that is similar to that of linaclotide. It is thought to act locally
within the acidic regions of the intestines (the proximal duode-
num and cecum), thus reducing the likelihood of unwanted side
effects related to systemic absorption. It has been proposed for
IBS-C [118]. Elobixibat (A3309) is a minimally absorbed ileal bile
acid transporter inhibitor that reduces the ileal reabsorption of bile
acids and increases propulsive contractions and secretion in the
colon and bowel frequency [119].
5. Conclusions and perspectives
Over the last ten years, many myths and misconceptions have
been abandoned [27], but there is certainly more to learn about
ways of optimising the diagnosis and treatment of chronic con-
stipation. This is particularly important because constipation is
common and has a substantial economic impact. There is an
increasing emphasis on evidence-based studies that demonstrate
the efﬁcacy of different treatments, but a substantial proportion of
patients are still dissatisﬁed. Such patients should be better deﬁned
taking into account both the subjective and objective components
of their dissatisfaction. Whether those deﬁned on the basis of pre-
cise and reproducible diagnostic tests might beneﬁt from speciﬁc
therapeutic approaches remains a challenging question for future
studies.
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